Uzi Yemin, Director of Delek US Holdings, Inc. (NYSE:DK) , reported an open-market sale of 34,026 shares for a total of ~$1.61 million on May 4, 2026, according to an SEC Form 4 filing . Transaction value based on SEC Form 4 reported price ($47.29); post-transaction value based on May 4, 2026, market close ($48.04). * 1-year price change calculated using May 4, 2026, as the reference date. Continu...
Uzi Yemin, Director of Delek US Holdings, Inc. (NYSE:DK) , reported an open-market sale of 34,026 shares for a total of ~$1.61 million on May 4, 2026, according to an SEC Form 4 filing . Transaction value based on SEC Form 4 reported price ($47.29); post-transaction value based on May 4, 2026, market close ($48.04). * 1-year price change calculated using May 4, 2026, as the reference date. Continue reading
Microvast Holdings press release ( MVST ): Q1 Non-GAAP EPS of -$0.04. Revenue of $60.6M (-48.0% Y/Y) misses by $38.42M . Gross margin decreased to 31.6% from 36.9% in Q1 2025. Non-GAAP adjusted gross margin decreased to 31.7% from 37.0% in Q1 2025, primarily due to lower production utilization which reduced fixed cost absorption. Operating expenses decreased to $27.1 million, compared to $29.2 mil...
Microvast Holdings press release ( MVST ): Q1 Non-GAAP EPS of -$0.04. Revenue of $60.6M (-48.0% Y/Y) misses by $38.42M . Gross margin decreased to 31.6% from 36.9% in Q1 2025. Non-GAAP adjusted gross margin decreased to 31.7% from 37.0% in Q1 2025, primarily due to lower production utilization which reduced fixed cost absorption. Operating expenses decreased to $27.1 million, compared to $29.2 million in Q1 2025. Non-GAAP adjusted operating expenses were $26.1 million, compared to $28.5 million in Q1 2025. Net profit of $48.2 million, compared to net profit of $61.8 million in Q1 2025. Non-GAAP adjusted net loss was $14.6 million, compared to non-GAAP adjusted net profit of $19.3 million in Q1 2025. More on Microvast Holdings Microvast: Growth Story At Risk As Backlog Continues To Shrink Microvast: Sell On Dismal Quarter And Poor Near-Term Prospects Microvast Holdings, Inc. 2025 Q4 - Results - Earnings Call Presentation Microvast Holdings Q1 2026 Earnings Preview Quant snapshot: Beachbody, Deutsche Telekom among top-rated names as IceCure Medical, Fold Holdings lag
MFA Financial (NYSE:MFA) reported a negative total economic return for the first quarter of 2026 as higher rates, wider mortgage spreads and market volatility weighed on book value, while management pointed to portfolio growth, securitization activity and cost reductions as key p
MFA Financial (NYSE:MFA) reported a negative total economic return for the first quarter of 2026 as higher rates, wider mortgage spreads and market volatility weighed on book value, while management pointed to portfolio growth, securitization activity and cost reductions as key p
3 Finance Stocks Leaving Coal in Investors StockingsMetLife (NYSE:MET) reported a strong start to 2026, with executives telling analysts that first-quarter results reflected broad-based growth across its operating businesses, favorable underwriting trends and disciplined capital
3 Finance Stocks Leaving Coal in Investors StockingsMetLife (NYSE:MET) reported a strong start to 2026, with executives telling analysts that first-quarter results reflected broad-based growth across its operating businesses, favorable underwriting trends and disciplined capital
VANCOUVER, British Columbia, May 11, 2026 (GLOBE NEWSWIRE) -- Liberty Gold Corp. (TSX:LGD; OTCQX:LGDTF) ("Liberty Gold" or the “Company”), is pleased to announce its financial and operating results for the quarter ended March 31, 2026. All amounts are presented in United States dollars unless otherwise stated.
VANCOUVER, British Columbia, May 11, 2026 (GLOBE NEWSWIRE) -- Liberty Gold Corp. (TSX:LGD; OTCQX:LGDTF) ("Liberty Gold" or the “Company”), is pleased to announce its financial and operating results for the quarter ended March 31, 2026. All amounts are presented in United States dollars unless otherwise stated.
It's probably to be expected from a stock named Rocket Lab (NASDAQ: RKLB) , but this company just keeps going up and up. I'm not just talking about the stock price, although Rocket Lab stock is up 51% already this year, including Friday's astounding 34% run after earnings . I'm talking about how well this rocket stock's business is on the ascent. Image source: Rocket Lab. Continue reading
It's probably to be expected from a stock named Rocket Lab (NASDAQ: RKLB) , but this company just keeps going up and up. I'm not just talking about the stock price, although Rocket Lab stock is up 51% already this year, including Friday's astounding 34% run after earnings . I'm talking about how well this rocket stock's business is on the ascent. Image source: Rocket Lab. Continue reading
Catawba River Capital disclosed a new position in Graham Corporation (NYSE:GHM) on May 11, 2026, acquiring 117,716 shares in a transaction estimated at $9.22 million based on quarterly average pricing. According to a Securities and Exchange Commission (SEC) filing dated May 11, 2026, Catawba River Capital initiated a new position in Graham Corporation, buying 117,716 shares. The estimated transact...
Catawba River Capital disclosed a new position in Graham Corporation (NYSE:GHM) on May 11, 2026, acquiring 117,716 shares in a transaction estimated at $9.22 million based on quarterly average pricing. According to a Securities and Exchange Commission (SEC) filing dated May 11, 2026, Catawba River Capital initiated a new position in Graham Corporation, buying 117,716 shares. The estimated transaction value is $9.22 million, calculated using the average share price for the quarter ended March 31, 2026. The quarter-end value of the position was $9.64 million, reflecting both the share purchase and any stock price changes during the period. Graham Corporation is a leading provider of specialized engineering solutions for critical applications across industrial and defense markets. The company's strategy centers on technical expertise, product reliability, and a diversified portfolio serving both commercial and government customers. Its competitive edge is built on decades of experience, a strong reputation for quality, and the ability to deliver custom solutions for complex operational needs. Continue reading
Ovintiv press release ( OVV ): Q1 GAAP EPS of -$2.35. Recognized a net loss on risk management in revenues of $63 million, before tax Generated cash from operating activities of $1.1 billion and Non-GAAP Cash Flow of $1.2 billion First quarter average total production volumes were approximately 679 MBOE/d, including 225 Mbbls/d of oil and condensate, 100 Mbbls/d of other NGLs (C2 to C4) and 2,124 ...
Ovintiv press release ( OVV ): Q1 GAAP EPS of -$2.35. Recognized a net loss on risk management in revenues of $63 million, before tax Generated cash from operating activities of $1.1 billion and Non-GAAP Cash Flow of $1.2 billion First quarter average total production volumes were approximately 679 MBOE/d, including 225 Mbbls/d of oil and condensate, 100 Mbbls/d of other NGLs (C2 to C4) and 2,124 MMcf/d of natural gas; all products were at the high end of guidance First quarter capital investment of $605 million was at the low end of the guidance range of $600 million to $650 million First quarter upstream operating expense of $3.71 per BOE, upstream transportation and processing costs of $7.53 per BOE, production, mineral and other taxes of $1.30 per BOE, or 3.6% of upstream product revenue; costs were at the low end of guidance on a combined basis. Including the impact of hedges, first quarter average realized price for oil and condensate was $70.14 per barrel (98% of WTI), $18.12 per barrel for other NGLs, and $3.24 per Mcf (64% of NYMEX) for natural gas, resulting in a total average realized price of $36.08 per BOE 2026 GuidanceThe Company issued its second quarter 2026 guidance and reiterated its full year guidance. Full year production volumes are expected to average 620 to 645 MBOE/d, with full year expected capital investment of $2.25 billion to $2.35 billion. 2026 Guidance 2Q 2026 Full Year 2026 Total Production (MBOE/d) 610 – 635 620 – 645 Oil & Condensate (Mbbls/d) 200 – 205 205 – 212 NGLs (C2 to C4) (Mbbls/d) 75 – 80 80 – 85 Natural Gas (MMcf/d) 2,000 – 2,100 2,000 – 2,100 Capital Investment ($ Millions) $550 – $600 $2,250 – $2,350 Click to enlarge More on Ovintiv Ovintiv Vs. Paramount Resources: Why It's Time To Buy One And Sell The Other Ovintiv Inc. (OVV) Q4 2025 Earnings Call Transcript Ovintiv Inc. 2025 Q4 - Results - Earnings Call Presentation Ovintiv Q1 2026 Earnings Preview Shell's $16.4B deal for ARC Resources looks like fair value, analyst says
Recent consumer alert on ebike safety laws says some vehicles should be classified as mopeds or motorcycles Amazon said it plans to stop selling certain high-speed electric bicycles in California after a string of high-profile incidents and a consumer alert that the state attorney general issued last month. In April an 81-year-old man in Orange county died after a teenager illegally riding an e-mo...
Recent consumer alert on ebike safety laws says some vehicles should be classified as mopeds or motorcycles Amazon said it plans to stop selling certain high-speed electric bicycles in California after a string of high-profile incidents and a consumer alert that the state attorney general issued last month. In April an 81-year-old man in Orange county died after a teenager illegally riding an e-motorcycle struck him. The teen’s mother, Tommi Jo Mejer, has since been charged with involuntary manslaughter in Ed Ashman’s death as officials say she was warned it was illegal for her son to operate the vehicle. Continue reading...
Aktis Oncology, Inc. press release ( AKTS ): Net loss was $18.3 million for the quarter ended March 31, 2026, compared to $15.0 million for the comparable prior year period. The increase in net loss of $3.3 million was primarily driven by increased operating expenses. Collaboration revenue of $3.23M More on Aktis Oncology, Inc. Aktis Oncology: 'Buy' Based On Radiotherapeutic Isotope Design For Bro...
Aktis Oncology, Inc. press release ( AKTS ): Net loss was $18.3 million for the quarter ended March 31, 2026, compared to $15.0 million for the comparable prior year period. The increase in net loss of $3.3 million was primarily driven by increased operating expenses. Collaboration revenue of $3.23M More on Aktis Oncology, Inc. Aktis Oncology: 'Buy' Based On Radiotherapeutic Isotope Design For Broad Targeting Aktis Oncology, Inc. (AKTS) Presents at TD Cowen 46th Annual Health Care Conference - Slideshow Aktis Oncology, Inc. reports FY results Historical earnings data for Aktis Oncology, Inc. Financial information for Aktis Oncology, Inc.